AU2002367087A1 - Method for the treatment of mc receptor related disorders with a chelate and/or a chelator - Google Patents

Method for the treatment of mc receptor related disorders with a chelate and/or a chelator

Info

Publication number
AU2002367087A1
AU2002367087A1 AU2002367087A AU2002367087A AU2002367087A1 AU 2002367087 A1 AU2002367087 A1 AU 2002367087A1 AU 2002367087 A AU2002367087 A AU 2002367087A AU 2002367087 A AU2002367087 A AU 2002367087A AU 2002367087 A1 AU2002367087 A1 AU 2002367087A1
Authority
AU
Australia
Prior art keywords
chelator
chelate
treatment
related disorders
receptor related
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002367087A
Inventor
Birgitte Holst Lange
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
7TM Pharma AS
Original Assignee
7TM Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 7TM Pharma AS filed Critical 7TM Pharma AS
Publication of AU2002367087A1 publication Critical patent/AU2002367087A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002367087A 2001-12-21 2002-12-20 Method for the treatment of mc receptor related disorders with a chelate and/or a chelator Abandoned AU2002367087A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200101943 2001-12-21
DKPA200101943 2001-12-21
PCT/DK2002/000902 WO2003055477A1 (en) 2001-12-21 2002-12-20 Method for the treatment of mc receptor related disorders with a chelate and/or a chelator

Publications (1)

Publication Number Publication Date
AU2002367087A1 true AU2002367087A1 (en) 2003-07-15

Family

ID=8160929

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002367087A Abandoned AU2002367087A1 (en) 2001-12-21 2002-12-20 Method for the treatment of mc receptor related disorders with a chelate and/or a chelator

Country Status (2)

Country Link
AU (1) AU2002367087A1 (en)
WO (1) WO2003055477A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2462200A1 (en) 2001-08-10 2003-02-20 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
US20110009437A1 (en) * 2008-02-27 2011-01-13 Merck Patent Gesellschaft Mit Beschrankter Haftung Carboxamide-heteroaryl derivatives for the treatment of diabetes
JP2011057661A (en) * 2009-08-14 2011-03-24 Bayer Cropscience Ag Pesticidal carboxamides
GB201103578D0 (en) * 2011-03-02 2011-04-13 Sabrepharm Ltd Dipyridinium derivatives
US9278981B2 (en) 2012-05-15 2016-03-08 Novartis Ag Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
JP6204975B2 (en) 2012-05-15 2017-09-27 ノバルティス アーゲー Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
MX357305B (en) * 2012-05-15 2018-07-04 Novartis Ag Compounds and compositions for inhibiting the activity of abl1, abl2 and bcr-abl1.
LT2861579T (en) 2012-05-15 2018-05-10 Novartis Ag Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
CN108997225A (en) 2013-03-14 2018-12-14 特雷罗药物股份有限公司 JAK2 and ALK2 inhibitor and its application method
SG11202000230VA (en) 2017-07-11 2020-02-27 Vertex Pharma Carboxamides as modulators of sodium channels
CN108383791A (en) * 2018-04-27 2018-08-10 上海泰禾国际贸易有限公司 A kind of amides compound and its preparation method and application
JP2021530554A (en) 2018-07-26 2021-11-11 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド Methods and ACVR1 Inhibitors for Treatment of Diseases with Abnormal ACVR1 Expression

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169857A (en) * 1988-01-20 1992-12-08 Bayer Aktiengesellschaft 7-(polysubstituted pyridyl)-hept-6-endates useful for treating hyperproteinaemia, lipoproteinaemia or arteriosclerosis
US6284795B1 (en) * 1998-09-04 2001-09-04 Warner-Lambert Company Sulfonamide compounds and methods of treating atherosclerosis and restenosis
AU5874200A (en) * 1999-08-12 2001-03-13 Palatin Technologies, Inc. Melanocortin metallopeptide constructs, combinatorial libraries and applications
AU2844901A (en) * 1999-12-30 2001-07-16 7Tm Pharma A method of identifying ligands of biological target molecules
US6403618B1 (en) * 2000-02-15 2002-06-11 Novactyl, Inc. Agent and method for controlling angiogenesis

Also Published As

Publication number Publication date
WO2003055477A1 (en) 2003-07-10

Similar Documents

Publication Publication Date Title
AU2002348135A1 (en) Methods for the treatment of addiction
MXPA03007960A (en) Compounds and methods for the treatment of urogenital disorders.
HUP0402629A3 (en) 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
AU2003233010A8 (en) Process for the preparation of 3,3,4,4-tetrafluoropyrrolidine and derivatives thereof
HK1053058A1 (en) Use of pramipexole for the treatment of addictive disorders
AU6910600A (en) Methods for the treatment of mental disorders
AU2002367087A1 (en) Method for the treatment of mc receptor related disorders with a chelate and/or a chelator
HK1041827A1 (en) Compounds for the treatment of estrogen-defendent illnesses and methods for making and using the dame.
AU2001271887A1 (en) Methods for diagnosis and treatment of psychiatric disorders
AU5038299A (en) Process for the biocidal treatment of surfaces
EP1537083A4 (en) S-(-)-amlodipine nicotinate and process for the preparation thereof
AU2002236781A1 (en) Treatment for snoring
AU2002363935A1 (en) Composition and method for the treatment of anorectal disorders
AU7750100A (en) Method for the treatment of obesity
EP1578723A3 (en) Process for the preparation of oxazolidinones and method of use thereof
AU2002367959A1 (en) Process for the preparation of oxazolidinones and method of use thereof
HUP0401577A3 (en) Process for the preparation of 2,4-didezoxyhexoses and 2,4,6-tridezoxyhexoses
CZ20011872A3 (en) Isonipecotamides for the treatment of integrin-mediated disorders
IL154378A0 (en) Compounds for the treatment of addictive disorders
AU2080201A (en) Treatment of addiction disorders
AU2002363227A1 (en) Methods for the treatment and diagnosis of tumorigenic and angiogenic disorders using 32616
EP1315499A4 (en) Compositions and methods for the treatment of anorectal disorders
AU2002303162A1 (en) Il-1ss inhibition for myeloma and related disorders
AU2000272704A1 (en) Use of compounds for the treatment of obesity
IL160551A0 (en) Plaster for the treatment of dysfunctions and disorders of nails

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase